Captopril use was associated with a lower relative risk of developing prostate cancer (RR 0.7; 95% CI 0.4-1.2), whereas no clear association was found for other antihypertensive drugs.
Case-Control
Does captopril or other antihypertensive drugs affect the risk of prostate cancer in male patients aged 50-79 years?
There is no clear association between the use of most antihypertensive drugs and prostate cancer, though captopril users showed a trend toward lower risk that requires further research.
Estimación del efecto: RR 0.7 (95% CI 0.4-1.2)
BACKGROUND: There has been some debate on the existence of an association between hypertension, antihypertensive medications and cancer risk. METHODS: We performed a nested case-control study to assess the association between the risk of prostate cancer and the use of the angiotensin converting enzyme (ACE)-inhibitor captopril, and other antihypertensive drugs. We used data from the General Practice Research Database in UK. RESULTS: We found an incidence rate of prostate cancer of 1.61 per 1,000 person-years among male patients aged 50-79 years old. Patients with a history of benign prostatic hyperplasia and/or prostatism carried a two-fold greater risk of prostate cancer than those without such antecedents. None of the other studied co-morbidities were associated with prostate cancer. We found that users of captopril had a relative risk of 0.7 (95% CI: 0.4-1.2) to develope prostate cancer. None of the other studied individual ACE-inhibitors shared a similar effect with the one observed for captopril. CONCLUSIONS: No clear association was apparent between the use of antihypertensive drugs and prostate cancer. However, specific focus on users of captopril showed a lower risk of subsequent prostate cancer. Further research is needed to explore this association.
Ronquist et al. (Thu,) conducted a case-control in prostate cancer. captopril was evaluated on risk of prostate cancer (RR 0.7, 95% CI 0.4-1.2). Captopril use was associated with a lower relative risk of developing prostate cancer (RR 0.7; 95% CI 0.4-1.2), whereas no clear association was found for other antihypertensive drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: